Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Consolidated Net Income (2016 - 2025)

Historic Consolidated Net Income for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.7 million.

  • Corcept Therapeutics' Consolidated Net Income fell 5834.2% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.2 million, marking a year-over-year decrease of 2514.68%. This contributed to the annual value of $141.2 million for FY2024, which is 3304.03% up from last year.
  • According to the latest figures from Q3 2025, Corcept Therapeutics' Consolidated Net Income is $19.7 million, which was down 5834.2% from $35.2 million recorded in Q2 2025.
  • Corcept Therapeutics' Consolidated Net Income's 5-year high stood at $47.2 million during Q3 2024, with a 5-year trough of $15.8 million in Q1 2023.
  • For the 5-year period, Corcept Therapeutics' Consolidated Net Income averaged around $28.2 million, with its median value being $27.8 million (2024).
  • In the last 5 years, Corcept Therapeutics' Consolidated Net Income soared by 8907.43% in 2023 and then crashed by 5834.2% in 2025.
  • Over the past 5 years, Corcept Therapeutics' Consolidated Net Income (Quarter) stood at $32.1 million in 2021, then crashed by 48.2% to $16.6 million in 2022, then surged by 89.07% to $31.4 million in 2023, then fell by 1.96% to $30.8 million in 2024, then plummeted by 36.09% to $19.7 million in 2025.
  • Its Consolidated Net Income was $19.7 million in Q3 2025, compared to $35.2 million in Q2 2025 and $20.5 million in Q1 2025.